Rescheduling, Descheduling, and the Future of Financial Compliance

A pragmatic analysis of where cannabis banking is heading in 2026 and why regulatory uncertainty around rescheduling, intoxicating hemp, and interagency guidance is creating both risk and opportunity for financial institutions.

Cannabis banking in the United States is entering another period of structural tension.

Despite years of state-level legalization, federal frameworks remain largely unchanged. At the same time, Congress has quietly moved to restrict intoxicating hemp derivatives, introducing a new layer of uncertainty for banks that previously viewed hemp as a lower-risk alternative to marijuana-related businesses.

In a recent discussion between Chris Van Dyck (Cogent Law) and Steven Kemmerling (CRB Monitor), one message was clear:
2026 will not reward passive compliance strategies.

The Big Picture: Why 2026 Matters

Cannabis banking is not being reshaped by a single event, but by the convergence of three unresolved forces:

• Potential rescheduling of marijuana under the Controlled Substances Act
  
• A looming federal crackdown on intoxicating hemp-derived products
  
• Continued silence from FinCEN on updated cannabis banking guidance
  

Together, these dynamics are forcing banks, credit unions, and compliance teams to rethink how they classify risk, not just by product, but by flow of funds, jurisdiction, and regulatory durability.

Rescheduling: Why the Impact Is Being Overestimated

Rescheduling cannabis from Schedule I to Schedule III is often framed as a turning point. In practice, its immediate impact on banking is limited.

Key realities discussed during the session:

• Rescheduling affects drug classification, not banking permissibility
  
• Cannabis would still not be an FDA-approved pharmaceutical product
  
• FinCEN guidance would remain unchanged absent formal revision
  
• SAR filing, enhanced due diligence, and monitoring obligations would continue
  

Bottom line:
Rescheduling may reduce political stigma, but it does not materially alter BSA/AML obligations for financial institutions in the near term.

As noted in the discussion, nothing meaningfully changes for banks until FinCEN acts and there is little indication that it intends to.

FinCEN: The Guidance That Isn’t Moving

FinCEN’s marijuana banking guidance is now more than a decade old, and despite repeated calls from the industry and policymakers for revision, it continues to serve as the primary reference point for examiners. 

The discussion made clear that there is persistent internal reluctance within FinCEN to reopen or materially revise the guidance, in part due to recognition that the original framework created long-term operational and compliance burdens for financial institutions. 

Rather than leading reform efforts, FinCEN appears to favor deferring to broader interagency guidance, signaling an absence of appetite to reclaim ownership over cannabis banking policy.

For compliance teams, the implication is straightforward: the existing framework, imperfect, outdated, and often misaligned with current market realities, remains the law of the land.

The Hemp Shock: From “Lower Risk” to Regulatory Wildcard

Perhaps the most immediate disruption discussed was the quiet insertion of language into a federal spending bill effectively banning most intoxicating hemp-derived cannabinoids after a one-year window.

This matters because hemp had been treated differently by many institutions:

• Lower perceived compliance burden
  
• No rolling marijuana SAR requirements
  
• Fewer enhanced monitoring expectations
  
• Often banked outside formal CRB programs
  

That distinction is now collapsing.

Why This Creates Risk

• Many hemp businesses operate interstate
  
• State-level cannabis regimes are intrastate by design
  
• Federal prohibition of intoxicating hemp would undermine current operating models
  
• Banks could find themselves servicing businesses that are neither federally legal nor state-regulated
  

This is not a theoretical concern. It is a BSA problem in waiting.

Interstate vs. Intrastate: The Silent Fault Line

One of the most consequential insights from the conversation was the distinction between:

• Intrastate cannabis models, which align with existing state licensing frameworks
  
• Interstate hemp models, which rely on national distribution and centralized production
  

If intoxicating hemp is forced into state cannabis regimes, many existing businesses face structural collapse. The economics simply do not translate.

For banks, this distinction should drive immediate action:

• Segmentation of hemp portfolios
  
• Identification of interstate exposure
  
• Reclassification of risk ratings
  
• Reassessment of onboarding and monitoring assumptions
  

Lending Exposure: The Overlooked Risk

Depository risk is only part of the equation. The discussion underscored a more subtle, and often underestimated, threat: credit exposure tied to the broader hemp ecosystem. Many financial institutions have lending relationships connected to processing equipment, warehouses, manufacturing facilities, agricultural operations, and distribution infrastructure that support hemp-derived products. These exposures can become problematic quickly as regulatory uncertainty intensifies.

Even if enforcement actions are delayed or uneven, asset values and repayment capacity may deteriorate well before any formal regulatory resolution. For banks, this means that inaction is not neutral. Loan covenants should already be under review, hemp-related portfolios stress-tested, and conversations with borrowers’ CFOs initiated early. Institutions must also be prepared for the possibility of downgrades, restructurings, or other credit adjustments as market conditions evolve.

Ignoring this dimension of risk is how a compliance issue quietly transforms into a balance-sheet problem.

What Banks Should Be Doing Now

Across the discussion, several practical themes emerged. Financial institutions should already be:

• Conducting portfolio scrubs to identify hemp and IHP exposure
  
• Differentiating interstate vs. intrastate operations
  
• Preparing customer communications and internal Q&A
  
• Considering temporary pauses on new hemp onboarding
  
• Evaluating whether IHP accounts should be treated akin to CRBs
  
• Erring on the side of over-filing rather than under-filing
  

Waiting for legislative clarity is not a strategy. It is a risk posture.

SAFE Banking: Still a Question Mark

While the SAFE (or SAFER) Banking Act continues to surface as a potential solution, expectations remain muted.

Despite bipartisan support:

• Legislative priorities remain elsewhere
  
• Timing remains unpredictable
  
• Passage would still require regulatory follow-through
  

The consensus view was cautious at best:
SAFE Banking may help, but it should not be relied upon in near-term planning.

Looking Ahead to 2026

Cannabis banking remains a high-risk activity, not because institutions lack tools, but because regulatory alignment remains incomplete.

The most resilient programs will be those that:

• Assume guidance does not change
  
• Treat compliance as an operating function, not a workaround
  
• Build flexibility into onboarding, monitoring, and exit strategies
  
• Communicate early and often with customers and boards
  

In cannabis banking, uncertainty is permanent.
Preparedness is optional and increasingly decisive.